Lee Gilho, Park Heeyoon, Seo Yumi, Lee Seung-Ju
Department of Urology, Dankook University College of Medicine, Cheonan, Korea.
Department of Urology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Investig Clin Urol. 2025 Sep;66(5):455-461. doi: 10.4111/icu.20250106.
Antimicrobial-resistant (AMR) has become a global concern. To assess AMR patterns in Korea, we analyzed the genetic diversity of the AMR-determining sites (ARDS) in across in 285 samples collected over two decades.
-positive samples were collected from various groups: males at one referral center (ORC) from 2014 to 2019 (G1; 43) and from 2020 to 2023 (G2; 54), males at primary care clinics (PCCs) in 2018-2019 (G3; 84), female sex workers at a regional healthcare center in 2004 (G4; 51), and females at PCCs in 2018-2019 (G5; 53). Sanger sequencing was performed at positions 2058/2059 in the 23S rRNA gene and positions GyrA95, GyrA99, ParC83, and ParC87 of topoisomerase IV genes in .
In 2004, mutations were rare with S83I (0.0%), M95I (3.4%), and A2059G (10.5%). By 2020-2023, ARDS mutations had become common, peaking at S83I (83.3%) and A2059G (70.4%). No sex differences were observed in ARDS mutations between G3 and G5. A comparison of mutations in males at the ORC showed significant differences in A2059G and S83I between pre-2020 (G1) and post-2020 (G2). Males at the ORC (G1) had higher mutation rates in A2059G, GyrA95, and GyrA99 compared to males at PCCs (G3).
Currently, referred males exhibit a rapid increase in AMR, and the synergy between A2059G and S83I/R/N mutations raises concerns regarding the emergence of pan-drug-resistant , potentially leading to an irreversible crisis in treatment options in Korea.
抗菌药物耐药性(AMR)已成为全球关注的问题。为评估韩国的AMR模式,我们分析了二十多年来收集的285份样本中AMR决定位点(ARDS)的遗传多样性。
从不同组收集阳性样本:2014年至2019年在一个转诊中心(ORC)的男性(G1组;43例)和2020年至2023年的男性(G2组;54例),2018 - 2019年基层医疗诊所(PCCs)的男性(G3组;84例),2004年在一个地区医疗中心的女性性工作者(G4组;51例),以及2018 - 2019年PCCs的女性(G5组;53例)。对23S rRNA基因的2058/2059位点以及拓扑异构酶IV基因的GyrA95、GyrA99、ParC83和ParC87位点进行桑格测序。
2004年,S83I(0.0%)、M95I(3.4%)和A2059G(10.5%)的突变很少见。到2020 - 2023年,ARDS突变变得普遍,S83I(83.3%)和A2059G(70.4%)达到峰值。G3组和G5组在ARDS突变方面未观察到性别差异。对ORC男性的突变比较显示,2020年前(G1组)和2020年后(G2组)在A2059G和S83I方面存在显著差异。与PCCs的男性(G3组)相比,ORC的男性(G1组)在A2059G、GyrA95和GyrA99方面的突变率更高。
目前,转诊的男性中AMR迅速增加,A2059G与S83I/R/N突变之间的协同作用引发了对泛耐药菌出现的担忧,这可能导致韩国治疗选择出现不可逆转的危机。